Monopar Therapeutics Inc. announced its financial results for the second quarter ended June 30, 2025, on August 12, 2025. The company reported $53.3 million in cash, cash equivalents, and investments as of June 30, 2025.
The net loss for the second quarter of 2025 was $2.5 million, or $0.35 per share, compared to a net loss of $1.7 million, or $0.49 per share, for the second quarter of 2024. Research and development expenses increased by $599,023 to $1,730,000, primarily due to higher R&D personnel expenses.
General and administrative expenses rose by $846,489 to $1,504,295, mainly due to increased Board compensation, G&A personnel expenses, and legal fees. Interest income increased by $707,294 due to higher cash balances. Monopar also noted that Alexion Pharmaceuticals officially transferred sponsorship of the investigational new drug (IND) application for ALXN1840 to Monopar on June 6, 2025, with FDA acknowledgment on July 29, 2025, making Monopar fully responsible for the program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.